Neurology: Volume 98, Number 9, March 1, 2022 Exam #2 - Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis
About this course
- Released: 03/01/2022
- Expires: 03/01/2025
EFFICACY AND SAFETY OF SELUMETINIB IN PEDIATRIC PATIENTS WITH NEUROFIBROMATOSIS TYPE 1: A SYSTEMATIC REVIEW AND META-ANALYSISUpon completion of the article by Hwang et al, the participant should be able to:
- State the pooled objective response rate of selumetinib in patients with neurofibromatosis type 1 (NF1) found in this study
- Identify commonly seen adverse effects of selumetinib in the treatment of NF1 observed in this meta-analysis
- Describe the characteristics of elevated creatine kinase (CK) levels seen during the course of selumetinib treatment for NF1 in this study
The article by Hwang et al covers the following core competency:
- Medical Knowledge
AUTHOR DISCLOSURES:Refer to listing above the references in each article.
THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES
The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MISSION STATEMENT/PROGRAM OBJECTIVES
After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
AMA CREDIT DESIGNATION STATEMENT
The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Journal Editors: James W.M. Owens, Jr., MD, PhD: Scientific Advisory Boards: Member of data safety monitoring board, RaSURE study, AADi Bioscience, Inc. Funding for travel or speaker honoraria: Honoraria, Program Director, AAN Annual Meeting. Editorial Boards: CME Editor, Neurology and Adam Kelly, MD: Editorial Boards: Neurology, CME editor, ongoing since January 2016. Other activities: Question writing for American Academy of Neurology activities, including Continuum. AAN staff members editing the test (K. Aman Ramm, H. McNiff) have no disclosures. All relevant financial relationships have been mitigated.
This CME program receives no commercial support.